Form 4: Akero COO Sells Shares After Option Exercise

Akero Therapeutics' COO, Jonathan Young, exercised stock options and subsequently sold a portion of the acquired common stock under a pre-arranged trading plan.

Summary

• Jonathan Young, Chief Operating Officer of Akero Therapeutics, Inc. (AKRO), reported transactions on October 1, 2025.
• He acquired 12,500 shares of common stock by exercising stock options at a price of $21.10 per share.
• Concurrently, he disposed of a total of 12,500 shares of common stock through two separate sales.
• The first sale involved 8,299 shares at a weighted-average price of $47.644 per share, with prices ranging from $46.94 to $47.93.
• The second sale involved 4,201 shares at a weighted-average price of $47.984 per share, with prices ranging from $47.94 to $48.22.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan dated April 29, 2025.
• Following these transactions, Mr. Young directly beneficially owns 196,898 shares of common stock and 44,982 stock options.
• An additional 60,000 shares are held in three irrevocable trusts (EA, CM, and JL Irrevocable Trusts) for the benefit of his children, for which he disclaims beneficial ownership.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions under a pre-arranged 10b5-1 plan, which is generally considered neutral in terms of company sentiment. The officer realized a gain, which is positive for the individual, but the sale itself is a standard part of executive compensation management.

Positives

• The exercise of stock options indicates that the Chief Operating Officer saw value in acquiring shares at the exercise price of $21.10.
• The subsequent sale of shares at weighted-average prices of $47.644 and $47.984 demonstrates a significant realized gain on the exercised options.

Negatives

• Insider selling, even when pre-planned under a Rule 10b5-1 plan, can sometimes be perceived negatively by the market, although the pre-arranged nature mitigates concerns about opportunistic timing.

Future Outlook

This Form 4 filing reports past insider transactions and does not contain any forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Management Comments

• The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated April 29, 2025, previously adopted by the Reporting Person.
• The Reporting Person disclaims beneficial ownership of securities held in irrevocable trusts for his children, stating that the filing is not an admission of beneficial ownership for Section 16 or any other purpose.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are a routine part of executive compensation and personal financial management in publicly traded companies. Such filings provide transparency into executive stock ownership changes but do not typically reflect new company-specific news or broader industry trends, unless the volume or nature of the transactions is highly unusual.

Corporate Governance

Related Party Transactions

• 60,000 shares of common stock are held in three irrevocable trusts (EA Irrevocable Trust, CM Irrevocable Trust, JL Irrevocable Trust) for the benefit of the Reporting Person's children, with the Reporting Person's spouse as trustee. The Reporting Person disclaims beneficial ownership of these securities.

Stakeholder Impact

• Shareholders receive transparency regarding changes in the Chief Operating Officer's direct and indirect beneficial ownership of company stock.
• The execution of transactions under a Rule 10b5-1 plan provides assurance to investors that insider trades are pre-scheduled and not based on immediate, undisclosed material information.

Key Dates

Keywords

Akero Therapeutics, AKRO, Form 4, Insider Transaction, Stock Options, Rule 10b5-1, Jonathan Young, Beneficial Ownership